Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer ...

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd ...

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

In this article, we are going to take a look at where Haemonetics Corporation (NYSE:HAE) stands against other top pro-life companies to invest in now. Investing isn’t just about numbers—it’s ...

On the actor's birthday, here's looking at his gritty and intense roles With his sweet and saccharine charm, Jung Hae-in is often linked to romantic K-dramas—no surprise, given his success in ...

oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor ...

Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...